clinical-stage biopharma company Atai Life Sciences ATAE Announces the Dose of the First Subject in Phase 1 Intravenous-to-Subcutaneous of Perception Neuroscience, a Majority-Owned Subsidiary bridging study Proprietary R-ketamine, PCN-101’s.
Open-label, trial set out to assess the safety, tolerability and pharmacokinetic profile of PCN-101 at 60mg, 90mg and 120mg subcutaneously compared to 60mg compound given intravenously in 16 healthy volunteers in four groups Has been given.
PCN-101 is a single isomer of ketamine and belongs to a new generation of glutamate receptor modulators – pharmacologically, it acts as a non-competitive NMDA receptor antagonist – that exhibit fast-acting antidepressant activity and anti-suicidality effects. has the capability of
Although Atai’s Phase 2a study on a single IV administration of 30mg and 60mg PCN-101 in patients with treatment-resistant depression did not reach the primary endpoint, it “demonstrated an encouraging safety profile and signs of efficacy at all time points” of two weeks, potentially indicating a sustained duration of impact,” the company says.
The current IV-to-subcutaneous bridging study, expected to be completed in mid-2023, will potentially inform future studies on the dosage of the new subcutaneous formulation of PCN-101, which rapidly induces R-ketamine. Supports further exploration of the potential of Acting antidepressant for home use.
Benzinga’s Psychedelics Capital Conference
PCC Happened on April 13 in Miami. For those who could not attend, here are some of the highlights of the conference:
Photo: Benzinga edit with photos by True Touch Lifestyle on Shutterstock and Wikimedia Commons.